Open-Label Safety, Tolerability, PK Study of IV CXA-10 Emulsion in Subjects in Chronic Kidney Injury
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The main purpose of this trial is to demonstrate the safety, tolerability and
pharmacokinetics (PK) of CXA-10, at potentially therapeutic doses, in the target patient
population comprised of subjects with Stage 3 and 4 chronic kidney injury (CKI). In addition,
associated pharmacodynamic (PD) effects of CXA-10 will be investigated.